{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:59:55Z","timestamp":1780394395447,"version":"3.54.1"},"reference-count":11,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background\/Objectives<\/jats:title><jats:p>Clinical trials of dupilumab have shown efficacy in treating moderate\u2010to\u2010severe atopic dermatitis (<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>) in adult patients. While a phase 2 trial of dupilumab has shown efficacy and safety in children, the medication awaits Food and Drug Administration (FDA) approval, and off\u2010label use is limited by dosing currently available to adults. We present this case series to describe the efficacy and safety profile of off\u2010label dupilumab use in six pediatric patients treated by one provider in a private practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective chart review of all patients under the age of 18 receiving dupilumab for <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>. Two dosing regimens were used as follows: adult dose for patients \u2265 40\u00a0kg and half dose for those &lt; 40\u00a0kg. We recorded the investigator's global assessment (<jats:styled-content style=\"fixed-case\">IGA<\/jats:styled-content>) and body surface area (<jats:styled-content style=\"fixed-case\">BSA<\/jats:styled-content>) prior to dupilumab initiation and following treatment. All patients were warned of potential side effects including injection site reaction, conjunctivitis, increased risk of infection, and lack of information about use in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six pediatric patients were identified with an average age of 10.8\u00a0years (range: 7\u201015). All patients had a decrease in <jats:styled-content style=\"fixed-case\">IGA<\/jats:styled-content> of at least 2 points using biweekly 300 or 150\u00a0milligram (mg) doses for an average treatment duration of 8.5\u00a0months (range: 6\u201011). Three patients (50%) had an <jats:styled-content style=\"fixed-case\">IGA<\/jats:styled-content> of 1 after treatment. No side effects were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Dupilumab appears to be an effective treatment for <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> in pediatric patients. Optimal dose and delivery have yet to be determined.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pde.13697","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T04:04:57Z","timestamp":1539921897000},"page":"85-88","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Long\u2010term off\u2010label dupilumab in pediatric atopic dermatitis: A\u00a0case series"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-1701","authenticated-orcid":false,"given":"Alison D.","family":"Treister","sequence":"first","affiliation":[{"name":"Department of Dermatology Feinberg School of Medicine Northwestern University Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-0152","authenticated-orcid":false,"given":"Peter A.","family":"Lio","sequence":"additional","affiliation":[{"name":"Department of Dermatology Feinberg School of Medicine Northwestern University Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00389-X"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.012"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12270"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12095"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.030"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.05.049"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.11.031"},{"key":"e_1_2_7_11_1","article-title":"Pharmacokinetics, safety, and efficacy of dupilumab in a pediatric population with moderate\u2010to\u2010severe atopic dermatitis: results from an open\u2010label phase 2a trial","author":"Cork MJ","journal-title":"Presented at 75th Annual Meeting of the American Academy of Dermatology"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.054"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.13697","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.13697","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pde.13697","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.13697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T12:13:32Z","timestamp":1694002412000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.13697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,18]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/pde.13697"],"URL":"https:\/\/doi.org\/10.1111\/pde.13697","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,18]]},"assertion":[{"value":"2018-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}